drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous PSMA-specific chimeric antigen receptor T cells; patient T cells engineered to express a CAR that recognizes prostate-specific membrane antigen (PSMA), leading to T-cell activation and cytotoxic killing of PSMA-positive prostate cancer cells. Administered as a single infusion, with or without prior lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a PSMA-specific chimeric antigen receptor. Upon binding PSMA on prostate cancer cells, the CAR triggers T-cell activation, proliferation, cytokine release, and targeted cytotoxic killing of PSMA-positive tumor cells; lymphodepletion may be used to enhance CAR-T expansion and activity.
drug_name
CART-PSMA
nct_id_drug_ref
NCT05656573